Zymeworks signs global licensing and collaboration deal with Roche for ZW209
ZYME•Zymeworks and Roche entered an exclusive global licensing collaboration for ZW209, subject to antitrust clearance. The deal includes $55 million upfront, $40 million upon Phase 1b initiation, up to $718 million in additional milestones and tiered royalties.
1. Deal terms and development
Roche will pay Zymeworks $55 million upfront and $40 million upon initiation of Phase 1b, with up to $718 million in additional milestone payments and tiered royalties ranging from high single digits to mid-teens on global net sales. Roche will fund Zymeworks’ Phase 1a monotherapy trial and take responsibility for subsequent global development and commercialization of the DLL3-targeting cancer therapy. The deal is subject to antitrust clearance, and patent protection extends into the 2040s.
